{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:53Z","timestamp":1784700413987,"version":"3.55.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Adoptive tumor-infiltrating lymphocyte (TIL) therapy is an established personalized cellular immunotherapy with demonstrated activity in selected solid tumors, particularly metastatic melanoma. However, clinical outcomes, safety, and manufacturing feasibility vary across tumor types and treatment strategies. This systematic review evaluates the efficacy, safety, and operational characteristics of TIL therapy across solid malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review was conducted in accordance with PRISMA guidelines. PubMed, Scopus, the Cochrane Central Register of Controlled Trials, and the WHO International Clinical Trials Registry Platform were searched from inception to 31 December 2025. Eligible studies included clinical trials and observational studies evaluating autologous TIL therapy in solid tumors. Due to substantial clinical and methodological heterogeneity, quantitative synthesis was restricted to clinically comparable cohorts, predominantly melanoma studies reporting objective response rates (ORR). A single-arm random-effects meta-analysis using the Freeman-Tukey transformation was performed. All other outcomes, including survival, safety, manufacturing success, and resection-to-infusion time, were synthesized narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-eight studies were included: 5 randomized controlled trials (RCTs), 22 prospective non-randomized studies, and 11 retrospective analyses, spanning melanoma and 8 other solid tumour types. Meta-analysis of 18 melanoma single-arm cohorts demonstrated a pooled objective response rate (ORR) of 42% (95% CI 37%\u201347%; I\u00b2 = 33.1%; prediction interval 29%\u201356%) under a random-effects model. In the phase III RCT (Rohaan et\u00a0al.), TIL therapy produced superior ORR (49% vs. 21%) and progression-free survival (median 7.2 vs. 3.1 months; HR 0.50, 95% CI 0.35\u20130.72) compared with ipilimumab. Subgroup analysis by TIL product type revealed a statistically significant difference (\u03c7\u00b2 = 7.25, p = 0.0266): tumor-reactive TIL products pre-screened ex vivo for antigen-specific reactivity showed the highest pooled ORR at 50% (95% CI 35%\u201364%), followed by young TIL at 43% (95% CI 29%\u201358%) and bulk TIL at 36% (95% CI 31%\u201342%); this observation is based on only 4 cohorts with a limited aggregate patient number and should be regarded as hypothesis-generating. No significant difference in ORR was observed by lymphodepletion status (p = 0.9544). Evidence in non-melanoma solid tumours was limited and heterogeneous, with generally lower response rates. Safety profiles were consistent across studies and primarily attributable to lymphodepleting chemotherapy and interleukin-2 administration, including haematologic and cytokine-related toxicities; treatment-related mortality was uncommon. Manufacturing success rates were high across contemporary cohorts, with a resection-to-infusion time typically spanning 4\u20136 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TIL therapy demonstrates consistent and clinically meaningful antitumor activity in melanoma, while evidence in non-melanoma tumors remains limited and heterogeneous. Future studies should prioritize biomarker-driven patient selection, optimization of manufacturing and conditioning strategies, and rational combination approaches to expand its applicability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420261291389.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1859306","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:54:13Z","timestamp":1784699653000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Haripriya Parapparambil","family":"Surendran","sequence":"first","affiliation":[{"name":"Indo-American Cancer Research Foundation, Basavatarakam Indo-American Cancer Hospital and Research Institute","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Gopisetty","sequence":"additional","affiliation":[{"name":"Indo-American Cancer Research Foundation, Basavatarakam Indo-American Cancer Hospital and Research Institute","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil Jagannathan","family":"Rajappa","sequence":"additional","affiliation":[{"name":"Basavatarakam Indo-American Cancer Hospital and Research Institute","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Subramanyeshwar","family":"Rao","sequence":"additional","affiliation":[{"name":"Basavatarakam Indo-American Cancer Hospital and Research Institute","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Unnikrishnan","sequence":"additional","affiliation":[{"name":"Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham","place":["Ernakulam, Kerala, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665488","article-title":"Recent advances in adoptive cell therapy for cancer immunotherapy","volume":"16","author":"Qian","year":"2025","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.11.013","article-title":"The clinical TIL experience in melanoma: Past, present, future","volume":"31","author":"Smithy","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.11.014","article-title":"Tumor-infiltrating lymphocyte therapy: A new frontier","volume":"31","author":"Tseng","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174160","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: Progressions and challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/CJI.0b013e3181d367bd","article-title":"Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy","volume":"33","author":"Prieto","year":"2010","journal-title":"J Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111548","article-title":"The role of dendritic cells in cancer immunity and therapeutic strategies","volume":"128","author":"Tai","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"104671","DOI":"10.1016\/j.critrevonc.2025.104671","article-title":"Outcomes of tumor-infiltrating lymphocyte therapy in solid tumours \u2013 A systematic review and meta analysis","volume":"209","author":"Mony","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.723","article-title":"Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: Updated systematic review and meta-analysis","volume":"35","author":"Mart\u00edn-Lluesma","year":"2024","journal-title":"Ann Oncol"},{"key":"B9","unstructured":"Prospero"},{"key":"B10","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/BMJ.L4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Online)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-002-0315-1","article-title":"Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma","volume":"51","author":"Dr\u00e9no","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02572-1","article-title":"Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: Results from a multicentre, randomized clinical phase III trial","volume":"69","author":"Khammari","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/bf02172659","article-title":"Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: A pilot study","author":"Baars","year":"1992"},{"key":"B16","article-title":"Study details _ NCT01701674 _ ipilimumab with lymphodepletion plus adoptive cell transfer and high dose IL-2 in melanoma mets pts _ clinicalTrials.gov","year":""},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","volume":"35","author":"Pilon-Thomas","year":"2012","journal-title":"J Immunotherapy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1479-5876-10-169","article-title":"Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients","volume":"10","author":"Ellebaek","year":"2012","journal-title":"J Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/J.1365-2567.1998.00419.X","article-title":"Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype","volume":"93","author":"Medina","year":"1998","journal-title":"Immunology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1691-7","article-title":"Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-\u03b3) in metastatic melanoma patients","volume":"64","author":"Khammari","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated il2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: A single-centre, two-stage, single-arm, phase 2 study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3649","article-title":"Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: Response, impact of anti-CTLA4, and biomarkers to predict clinical outcome","volume":"24","author":"Forget","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B29","doi-asserted-by":"publisher","article-title":"EU Clinical Trials Register Clinical trial results: T-cell therapy in combination with vemurafenib for BRAF mutated metastatic melanoma Summary Results information Trial information","year":"","DOI":"10.1093\/annonc\/mdx711.079"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: Boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"Van Den Berg","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15009","article-title":"Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors","volume":"112","author":"Hirai","year":"2021","journal-title":"Cancer Sci"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","author":"Sarnaik","year":"2021"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"100728","DOI":"10.1016\/j.iotech.2024.100728","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma","volume":"24","author":"K\u00f6nig","year":"2024","journal-title":"Immuno-Oncology Technol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3530148","DOI":"10.1155\/2018\/3530148","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in advanced melanoma patients","volume":"2018","author":"Saint-Jean","year":"2018","journal-title":"J Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000223","article-title":"Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic melanoma patients with and without brain metastases","volume":"41","author":"Mehta","year":"2018","journal-title":"J Immunother"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02348","article-title":"Adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic acral lentiginous melanoma","volume":"43","author":"Mcclelland","year":"2025","journal-title":"J Clin Oncol"},{"key":"B38","unstructured":"Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes1\n          \n          \n            \n              Fujita\n              K\n            \n            \n              Ikarashi\n              H\n            \n            \n              Takakuwa\n              K\n            \n            \n              Kodama\n              S\n            \n            \n              Tokunaga\n              A\n            \n            \n              Takahashi\n              T\n            \n          \n          \n          1995"},{"key":"B39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jso.20066","article-title":"Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis","volume":"87","author":"Gardini","year":"2004","journal-title":"J Surg Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1939","article-title":"Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic Malignant melanoma and renal cell carcinoma: A pilot study","volume":"13","author":"Goedegebuure","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19960715)78:2<244::aid-cncr9>3.0.co;2-l","article-title":"A randomized trial of adoptive lmmunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma","author":"Ratto","year":""},{"key":"B42","doi-asserted-by":"publisher","first-page":"112965","DOI":"10.1016\/j.ejca.2023.112965","article-title":"A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients","volume":"191","author":"Liang","year":"2023","journal-title":"Eur J Cancer"},{"key":"B43","unstructured":"Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer\n          \n          \n            \n              Kverneland\n              AH\n            \n            \n              Pedersen\n              M\n            \n            \n              Christine\n              M\n            \n            \n              Westergaard\n              W\n            \n            \n              Nielsen\n              M\n            \n            \n              Holz Borch\n              T\n            \n          \n          \n          2020"},{"key":"B44","unstructured":"A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma\n          \n          \n            \n              Jiang\n              SS\n            \n            \n              Tang\n              Y\n            \n            \n              Zhang\n              YJ\n            \n            \n              Weng\n              DS\n            \n            \n              Zhou\n              ZG\n            \n            \n              Pan\n              K"},{"key":"B45","doi-asserted-by":"publisher","article-title":"Study results _ NCT03083873 _ study of LN-145_LN-145-S1 autologous tumor infiltrating lymphocytes in the treatment of squamous cell carcinoma of the head & Neck _ clinicalTrials.gov","year":"","DOI":"10.32388\/8xfmv9"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/J.JBO.2020.100332","article-title":"Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma","volume":"25","author":"Wang","year":"2020","journal-title":"J Bone Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.09.026","article-title":"Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept","volume":"58","author":"Sherif","year":"2010","journal-title":"Eur Urol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2103","article-title":"Combination nivolumab, CD137 agonism, and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"28","author":"Hall","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00044","article-title":"Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"8","author":"Mullinax","year":"2018","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2546402","article-title":"Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma","volume":"14","author":"Hasanov","year":"2025","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2024.40495","article-title":"NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial","volume":"63","author":"L\u2019orphelin","year":"2024","journal-title":"Acta Oncol (Madr)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02170","article-title":"Breast cancers are immunogenic: Immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002449","article-title":"Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma","volume":"9","author":"Saberian","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-999-0272-4","article-title":"Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: A phase I\/II pilot trial","author":"Queirolo","year":"1999"},{"key":"B57","doi-asserted-by":"publisher","first-page":"7681","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Luksza","year":"2017","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/S12916-021-02006-4","article-title":"Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors","volume":"19","author":"Wang","year":"2021","journal-title":"BMC Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","article-title":"Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors","volume":"42","author":"Espinosa-Carrasco","year":"2024","journal-title":"Cancer Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/J.CCELL.2020.08.005","article-title":"Conserved Interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2023-008640","article-title":"Biomarkers for response to TIL therapy: a comprehensive review","volume":"12","author":"Albarr\u00e1n Fern\u00e1ndez","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1859306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:54:14Z","timestamp":1784699654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1859306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":62,"alternative-id":["10.3389\/fonc.2026.1859306"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1859306","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1859306"}}